Viewpoint on the role of tissue maintenance in ageing: focus on biomarkers of bone, cartilage, muscle, and brain tissue maintenance.
Viewpoint on the role of tissue maintenance in ageing: focus on biomarkers of bone, cartilage, muscle, and brain tissue maintenance. Ageing Res Rev. 2019 Sep 24;:100964 Authors: van der Spoel E, van Vliet NA, van Heemst D Abstract Specific hallmarks are thought to underlie the ageing process and age-related functional decline. In this viewpoint, we put forward the hypothesis that disturbances in the process of tissue maintenance are an important common denominator that may lie in between specific hallmarks of ageing (i.e. damage and responses to damage) and their ultimate (patho)physiological consequences (i.e. functional decline and age-related disease). As a first step towards verifying or falsifying this hypothesis, it will be important to measure biomarkers of tissue maintenance in future studies in different study populations. The main aim of the current paper is to discuss potential biomarkers of tissue maintenance that could be used in such future studies. Among the many tissues that could have been chosen to explore our hypothesis, to keep the paper manageable, we chose to focus on a selected number of tissues, namely bone, cartilage, muscle, and the brain, which are important for mobility and cognition and affected in several common age-related diseases, including osteoporosis, osteoarthritis, sarcopenia, and neurodegenerative diseases. Furthermore, we discuss their advantages and limitations for use in (pre)clinical studies. The proposed biomar...
Comorbidity and health care utilisation in persons with Sjögren's syndrome: a claims data analysis. Clin Exp Rheumatol. 2020 Sep 18; Authors: Albrecht K, Dörner T, Redeker I, Karberg K, Marschall U, Zink A, Callhoff J Abstract OBJECTIVES: To capture comorbidity and medication of persons with Sjögren's syndrome (SS) in a population-based cohort in comparison to matched controls. METHODS: Individuals with an outpatient diagnosis of M35.0 (ICD-10) in ≥2 quarters of a year or an inpatient diagnosis of M35.0 were identified in a German statutory health insurance fund covering 7.2 milli...
ConclusionsThis updated review provides an overview of recently published cost-effectiveness analyses. In comparison with a previous review, recent economic evaluations of anti-osteoporosis drugs were conducted in more countries and included more active drugs and sequential therapy as interventions/comparators. The updated economic evidence could help decision makers prioritize health interventions and the unmet/unreported quality issues indicated by the osteoporosis-specific guideline could be useful in improving the transparency, quality, and comparability of future economic evaluations in osteoporosis.
Abstract Our laboratories have used genetically engineered mouse models (GEMMs) to assess genetic contributions to skeletal diseases such as osteoporosis and osteoarthritis. Studies on the genetic contributions to OA are often done by assessing how GEMMs respond to surgical methods that induce symptoms modeling OA. Here, we will describe protocols outlining the induction of experimental OA in mice as well as detailed descriptions of methods for analyzing skeletal phenotypes using micro-computerized tomography and skeletal histomorphometry. PMID: 32979204 [PubMed - in process]
Conclusions The potential benefit of this standardized method is improved understanding of the relationship between objective measures of prosthesis alignment and various measures of patient outcomes and success such as pain, discomfort, and daily steps walked. A standardized means of calculating and expressing prosthesis alignment will also benefit the design and development of future alignment tool technology.
This study is the first to provide a direct link between this inflammation and plaque development - by way of IFITM3. Scientists know that the production of IFITM3 starts in response to activation of the immune system by invading viruses and bacteria. These observations, combined with the new findings that IFITM3 directly contributes to plaque formation, suggest that viral and bacterial infections could increase the risk of Alzheimer's disease development. Indeed, researchers found that the level of IFITM3 in human brain samples correlated with levels of certain viral infections as well as with gamma-secretase activ...
ConclusionComorbidities are common at MS symptom onset and increase with MS duration. Having MS may thus contribute to accrual of comorbidities. This emphasises the importance of optimal screening for and management of comorbidities in early MS and throughout the disease course.
A 70-year-old Caucasian female presented with multiple small, firm, yellowish nodules in the mucosa of the lower and upper lips, buccal mucosa, and dorsal and ventral surfaces of the tongue. Medical history of the patient included carpal tunnel syndrome surgery, systemic arterial hypertension, osteoarthritis, osteoporosis, and hypercholesterolemia. Laboratory tests showed serum levels of thyroid-stimulating hormone (TSH) at 6.56 UI/ µmL, leukocyte count of 3,400/mm³, and erythrocyte sedimentation rate of 36 mm/1 h.
(International Osteoporosis Foundation) The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF) have awarded the ESCEO-IOF Pierre Meunier Young Scientist Award to Dr. Daniel Pinto from the College of Health Sciences, Marquette University, and the Feinberg School of Medicine, Northwestern University, USA.
(International Osteoporosis Foundation) After the first fragility fracture, there is a high risk of subsequent fractures, with the risk highest in the following two years. This is why secondary fracture prevention, and specifically topics related to Post-fracture Care Coordination Program (such as Fracture Liaison Service - FLS) development, are a focus of several live and pre-recorded presentations at the virtual World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2020 from August 20-22, 2020.Several of these important sessions and related abstracts are highlighted.
(International Osteoporosis Foundation) Today, at the 2020 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, five investigators were awarded the first International Osteoporosis Foundation (IOF) Skeletal Rare Diseases Academy Awards in recognition of the quality of their research related to rare disorders of the skeleton.